Amundi Acquires 240,126 Shares of DaVita Inc. (NYSE:DVA)

Amundi increased its holdings in shares of DaVita Inc. (NYSE:DVA) by 116.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 446,386 shares of the company’s stock after purchasing an additional 240,126 shares during the period. Amundi owned 0.54% of DaVita worth $68,726,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. JPMorgan Chase & Co. grew its holdings in DaVita by 17.8% during the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after purchasing an additional 92,014 shares during the period. KBC Group NV lifted its position in DaVita by 0.8% during the fourth quarter. KBC Group NV now owns 316,155 shares of the company’s stock worth $47,281,000 after acquiring an additional 2,636 shares during the last quarter. BNP Paribas Financial Markets lifted its position in DaVita by 23.9% during the third quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company’s stock worth $47,874,000 after acquiring an additional 56,389 shares during the last quarter. Nordea Investment Management AB lifted its position in DaVita by 4.9% during the fourth quarter. Nordea Investment Management AB now owns 264,535 shares of the company’s stock worth $39,712,000 after acquiring an additional 12,339 shares during the last quarter. Finally, FMR LLC lifted its position in DaVita by 659.9% during the third quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after acquiring an additional 154,061 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

NYSE DVA opened at $146.71 on Wednesday. The firm’s fifty day moving average price is $159.41 and its two-hundred day moving average price is $157.90. The stock has a market cap of $11.74 billion, a PE ratio of 13.66, a PEG ratio of 1.07 and a beta of 0.99. DaVita Inc. has a fifty-two week low of $125.64 and a fifty-two week high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26.

DaVita (NYSE:DVA) last posted its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, equities analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Cowen restated a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. Barclays lifted their price target on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.